Statement on COVID-19

Statement on COVID-19

Published on 30/03/2020

Beginning of March 2020 Iris Biotech implemented measures in order to minimize the impact of and the risks associated with the current pandemic. As of 26 March 2020, Iris Biotech is classified as system-relevant.

The Bavarian Minister-President announced in a press conference on 20 March 2020 that in order to tackle the coronavirus pandemic by limiting social contacts, a statewide curfew would be imposed, effective 21 March.

 

Two weeks before, Iris Biotech already implemented measures in order to minimize the impact of and the risks associated with the current pandemic. In the interests of the safety and welfare of our team, we enabled as many staff members as possible to work from home. The rest of our staff has been spread over the now vacant offices, so that currently no more than two staff members are working in the same office. Moreover, our warehouse and laboratory staff are now working in different shifts.

Iris Biotech classified as system-relevant

As of 26 March 2020, Iris Biotech is classified as system-relevant for the purpose of maintaining health care as an organization that is part of the critical infrastructure, as stated by the administrative district office. We provide innovative compounds to researchers in biotech, pharma and academia who are working on treatments, vaccines and test kits for SARS-CoV-2. We are also in direct contact with leading research institutes working on this crucial issue. Even during this difficult period, we are certain to remain open for business and will continue to provide you with our customary high-quality material for both research and production.

 

Our thoughts and prayers are with the key people who keep this country running, especially healthcare workers, employees in the food industry, our police force, the Federal Agency for Technical Relief, the countless volunteers, as well as all the workers maintaining critical infrastructure.